W
e

e
k

 4
 

re
sp

o
n

se
 r

a
te

 (
%

)
W

e
e

k
 4

 
re

sp
o

n
se

 r
a

te
 (

%
)

75

50

25

100

0

BE SURE

76.5*

31.4

BKZ
(n=319)

ADA
(n=159)

BE VIVID

76.9*

15.3

BKZ
(n=321)

UST
(n=163)

BE RADIANT

47.3

71.0*

BKZ
(n=373)

SEC
(n=370)

BE READY

75.9

BKZ
(n=349)

75

50

25

100

0

BE SURE

15.4†

1.3

BKZ
(n=319)

ADA
(n=159)

BE VIVID

15.0†

1.2

BKZ
(n=321)

UST
(n=163)

BE RADIANT

6.2
13.9†

BKZ
(n=373)

SEC
(n=370)

BE READY

18.9

BKZ
(n=349)

75

50

25

100

0

BE SURE

39.5†

5.0

BKZ
(n=319)

ADA
(n=159)

BE VIVID

43.6†

3.1

BKZ
(n=321)

UST
(n=163)

BE RADIANT

17.6

35.9†

BKZ
(n=373)

SEC
(n=370)

BE READY

45.3

BKZ
(n=349)

75

50

25

100

0

BE SURE

37.6‡

25.8

BKZ
(n=319)

ADA
(n=159)

BE VIVID

37.4†

11.0

BKZ
(n=321)

UST
(n=163)

BE RADIANT

40.8

57.9†

BKZ
(n=373)

SEC
(n=370)

BE READY

43.0

BKZ
(n=349)

W
e

e
k

 4
 

re
sp

o
n

se
 r

a
te

 (
%

)
W

e
e

k
 4

 
re

sp
o

n
se

 r
a

te
 (

%
)

Summary

Presented at the 42nd Annual Fall Clinical Dermatology Conference  |  Las Vegas, NV  |  October 20–23, 2022

Objective
To evaluate early clinical and health-related quality 
of life (HRQoL) responses at Week 4 in patients with 
moderate to severe plaque psoriasis treated with 
bimekizumab (BKZ), adalimumab (ADA), ustekinumab 
(UST), and secukinumab (SEC) in four phase 3/3b trials.

Introduction
• Speed of response is an important treatment 

consideration for patients with plaque psoriasis;1  
90% of patients in a recent  
cross-sectional survey ranked rapid response as high 
importance, with an average expectation of complete 
skin clearance within 4 weeks.2

• Improvement in HRQoL is also an important treatment 
goal, given that psoriasis is a chronic disease and can 
place a significant burden on patients’ lives.3,4

Materials and Methods
• Data are reported in parallel from BE SURE,  

BE VIVID, BE RADIANT, and BE READY for patients  
who received BKZ 320 mg every 4 weeks (Q4W) or 
active comparators (Figure 1).5–8 

• We report the proportion of patients achieving a 
≥75% improvement from baseline in Psoriasis Area 
and Severity Index (PASI 75), PASI 90, PASI 100, and 
Dermatology Life Quality Index (DLQI) 0/1 at Week 4 
in each trial.

• Missing data were accounted for using non-responder 
imputation (NRI).

Results
• These analyses include 478 patients from BE SURE 

(319 BKZ; 159 ADA), 484 patients from BE VIVID (321 
BKZ; 163 UST), 743 patients from BE RADIANT (373 
BKZ; 370 SEC), and 349 patients from BE READY (349 
BKZ); baseline characteristics of these patients have 
been reported previously.5–8

• At Week 4, PASI 75, PASI 90, and PASI 100 were 
achieved by a greater proportion of BKZ-randomized 
patients vs active comparators (Figure 2).

• Furthermore, a greater proportion of patients 
randomized to BKZ vs active comparators achieved 
DLQI 0/1 at Week 4 (Figure 2). 

Conclusions
At Week 4, after one dose of BKZ, greater levels of 
skin clearance and HRQoL benefits were observed 
compared with two doses of ADA, one dose of UST, 
and four doses of SEC. 

Results were consistent across the four phase 
3/3b trials.

A. Blauvelt,1 K.C. Duffin,2 N. Magnolo,3 J. Weisman,4  
M. Ståhle,5 D. Wilsmann-Theis,6 M. Wang,7 K. Wixted,7  
B. Szilagyi,8 L. Puig9

Bimekizumab speed of response in patients with moderate to severe plaque 
psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE,  
and BE RADIANT)

Previously presented at SPIN 2022

Institutions: 1Oregon Medical Research Center, Portland, Oregon, USA; 2Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; 3Department of Dermatology, University Hospital Münster, Münster, Germany; 4Medical Dermatology Specialists, Inc., Atlanta, Georgia, USA; 5Department of Medicine, Karolinska Institutet, Solna, Sweden; 6University Hospital Bonn, University of 
Bonn, Bonn, Germany; 7UCB Pharma, Raleigh, North Carolina, USA; 8UCB Pharma, Monheim, Germany; 9Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. 

References: 1Kornmehl H et al. Dermatology 2021;237:151–157; 2Gorelick J et al. Dermatol Ther (Heidelb) 2019;9:785–797; 3Takeshita J et al. J Am Acad Dermatol 2017;76:377–390; 4Blauvelt A et al. J Drugs Dermatol 2020;19:487–492; 5Warren RB et al. N Engl J Med 2021;385:130–141, NCT03412747; 6Reich K et al. Lancet 2021;397:487–498, NCT03370133; 7Reich K et al. N Engl J Med 2021;385:142–152, NCT03536884; 8Gordon 
KB et al. Lancet 2021;397:475–486, NCT03410992. Author Contributions: Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: AB, KCD, NM, JW, MS, DWT, MW, KW, BS, LP; Drafting of the publication, or revising it critically for important intellectual content: AB, KCD, NM, JW, MS, DWT, MW, KW, BS, LP; Final approval of the publication: AB, KCD, NM, JW, MS, DWT, MW, KW, 
BS, LP. Author Disclosures: AB:Has served as a speaker (received honoraria) for AbbVie, Arcutis, Bristol Myers Squibb, Eli Lilly, Pfizer, Regeneron, Sanofi, and UCB Pharma, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, 
EcoR1, Eli Lilly, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB Pharma, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Amgen, 
Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Eli Lilly , Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB Pharma. KCD: Received grants/investigator for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Sienna, Stiefel, and UCB Pharma; speaker’s bureau for Novartis (non-promotional 
only); consultant/advisory board for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sienna, Stiefel, and UCB Pharma. NM: Honoraria for participation on advisory boards, as a speaker and for consultancy from AbbVie, Almirall, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and UCB Pharma. JW: Research grants from 
AbbVie, Amgen, Avillion, Boehringer Ingelheim, Bristol Myers Squibb, ChemoCentryx, Dermira, GSK, InflaRx, LEO Pharma, Janssen, Novartis, Pfizer, Regeneron, Sanofi, and UCB Pharma; consulting fees from AbbVie, Janssen, Novartis, Regeneron, Sanofi, and UCB Pharma; speaker’s bureau from AbbVie, Janssen, Novartis, Regeneron, and Sanofi. MS: Has received honoraria for participating in advisory boards and has given 
lectures for AbbVie, Celgene, Eli Lilly, LEO Pharma, Lipidor, Novartis, Pfizer, and UCB Pharma. DWT: Has been an advisor and/or received speakers’ honoraria or travel expense reimbursements and/or received grants and/or participated in clinical trials of the companies AbbVie, Almirall, Amgen, Beiersdorf, Biogen, Boehringer Ingelheim, Celgene, Forward Pharma, GSK, Janssen, LEO Pharma, Eli Lilly, Medac, Merck, Novartis, 
Pfizer, UCB Pharma, and VBL. MW, KW, BS: Employees and shareholders of UCB Pharma. LP: Received consultancy/speaker’s honoraria from and/or participated in trials sponsored by AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly, Gebro, Janssen, JS BIOCAD, LEO Pharma, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Samsung-Bioepis, Sandoz, Sanofi Genzyme, and UCB 
Pharma. Acknowledgements: This study was funded by UCB Pharma. We thank the patients and their caregivers in addition to the investigators and their teams who contributed to this study. The authors acknowledge Susanne Wiegratz, MSc, UCB Pharma, Monheim, Germany, for publication coordination, Natalie Nunez Gomez, MD, UCB Pharma, Monheim, Germany, for critical review, Yasha Najafi, MSc, Costello Medical, 
London, UK, for medical writing and editorial assistance and the Design team, Costello Medical, UK for graphic design assistance. All costs associated with development of this poster were funded by UCB Pharma.

Figure 1 Study design: Included patients

ADA: adalimumab; BKZ: bimekizumab; BSA: body surface area; DLQI: Dermatology Life Quality Index; HRQoL: health-related quality of life; PASI 75/90/100: ≥75%/≥90%/100% improvement from baseline in Psoriasis Area and Severity Index; Q2W: every 2 weeks; Q4W: every 4 weeks; Q12W: every 12 weeks; SEC: secukinumab; UST: ustekinumab.

PASI 75

Figure 2 Week 4 PASI 75, PASI 90, PASI 100, and DLQI 0/1 responses in BE SURE, BE VIVID, BE RADIANT, and BE READY (NRI)

p values for the comparison of treatment groups were based on the Cochran-Mantel-Haenszel test from the general association. In BE SURE, BE VIVID, and BE RADIANT, comparisons between BKZ and active comparators at Week 4 for PASI 90, PASI 100, and 
DLQI 0/1 were not pre-specified and therefore were not controlled for multiplicity; the corresponding p values are nominal for all trials. Comparisons for PASI 75 response at Week 4 were pre-specified and were controlled for multiplicity in all trials. *p<0.001 
vs active comparator; †nominal p<0.001 vs active comparator; ‡nominal p=0.010 vs active comparator.

BE VIVID and BE READY included placebo arms which were not included in these analyses. aAll patients randomized to bimekizumab received 320 mg Q4W; bAll patients randomized to adalimumab in BE SURE received 80 mg at baseline, 40 mg at Week 1, then Q2W; cPatients in BE VIVID received ustekinumab at baseline, Week 4, then Q12W. Ustekinumab dosing was based on patient weight 
at baseline: patients weighing ≤100 kg received one ustekinumab 45 mg injection and one placebo injection, patients >100 kg received two ustekinumab 45 mg injections; dAll patients randomized to secukinumab in BE RADIANT received 300 mg weekly to Week 4, then Q4W.

PASI 90

PASI 100 DLQI 0/1

BE READY⁸

0 4Week

BE SURE⁵

Bimekizumab 320 mga 
(n=319)

Adalimumab 40 mgb 
(n=159) 

N=478

BE RADIANT⁷BE VIVID⁶

0 4Week

Bimekizumab 320 mga 
(n=321)

Ustekinumab 45/90 mgc 
(n=163) 

N=484

0 4Week

Bimekizumab 320 mga 
(n=373)

Secukinumab 300 mgd 
(n=370) 

N=743

0 4Week

Bimekizumab 320 mga 
(n=349)

N=349

Dose schedule
80 mg dose 

Data are reported in parallel from  
the initial 4-week treatment period of  

BE SURE, BE VIVID, BE RADIANT,  
and BE READY

Bimekizumab
Adalimumab
Ustekinumab
Secukinumab

vs

At Week 4:

Greater  
skin clearance  

with bimekizumab;  
including higher rates  

of PASI 100

Health-related  
quality of life benefit  
with bimekizumab;  

as measured by  
DLQI 0/1